Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) on Monday published an update on its share buy-back programme launched on 1 September 2026, under which the company will repurchase shares for an amount up to DKK250m in September and October 2026.
As of 18 September 2026, the company had repurchased a total of 401,322 shares at an average price of DKK210.19 per share, for a total value of DKK84,353,084.
Following these transactions, Bavarian Nordic holds a total of 3,959,913 treasury shares, corresponding to 4.996% of the company's share capital.
AbbVie and Iambic agree collaboration for discovery and development of small molecule therapies
Bavarian Nordic reports purchases under share buy-back programme
Grunenthal to acquire Stivarga cancer treatment
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS
Coiled Therapeutics completes enrolment in two AO-252 formulation cohorts
Otsuka ICU Medical recalls 0.9% Sodium Chloride Injection
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma